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We have previously reported the time trends, design and interventions in randomised controlled trials (RCTs) in cystic fibrosis (CF) from
1961 through 1997 [Cheng K, Smyth RL, Motley J, O’Hea U, Ashby D, Randomised controlled trials in cystic fibrosis (1966–1997)
categorized by time, design, and intervention. Pediatr Pulmonol 2000, 29:1–7.]. We maintain an ongoing register of all RCTs and controlled
clinical trials (CCTs) in CF and have noted that in the five years since 1997 there has been a 48% increase in published trials. We aimed to
assess whether this increase has been associated with an improvement in design quality.
All RCTs and CCTs from 1961–2002 were assessed. Two epochs were then compared, 1961–1997 and 1998–2002. For each trial we
recorded the design, participant numbers and the intervention studied.
261 trials in 1998–2002 were compared with 544 trials in 1961–1997. Comparing the two epochs a similar proportion of trials were
parallel, double-blind and placebo controlled; also the median number of participants was similar. In the later epoch 25% of trials were
multicentre, compared with 11% previously.
Whilst this recent increase in clinical trials in CF is welcome, this has not been associated with improvements in quality. The trend for an
increasing proportion of trials to be multicentre is encouraging. There are however, still deficiencies in the design of clinical trials in CF.
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The need for RCTs and CCTs is increasingly being
recognised in CF. They are the most effective way not only
to assess new therapies (often funded by pharmaceutical
companies) but to compare the safety and effectiveness of
existing therapies, in areas where there may be little
commercial interest e.g. once daily aminoglycosides [3] or
comparison of dornase alpha and hypertonic saline [4].
The Cochrane Collaboration is an international organi-
sation that prepares, maintains and promotes the accessibil-
ity of systematic reviews of the effects of healthcare
interventions. The Cochrane Library [5] includes a database1569-1993/$ - see front matter D 2005 Published by Elsevier B.V. on behalf of E
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E-mail address: r.l.smyth@liverpool.ac.uk (R.L. Smyth).of systematic reviews and the Cochrane Central Register of
Controlled Trials (CENTRAL). CENTRAL contains biblio-
graphic details of controlled trials including full journal
publications and abstracts from conference proceedings.
The Cochrane Cystic Fibrosis and Genetic Disorders
Review Group co-ordinates the preparation and mainte-
nance of systematic reviews of RCTs in people with CF and
compiles a CF trials register for inclusion in The Cochrane
Library [5].
Controlled trials, such as those on the CF trials register,
are seen as the most robust of the available experimental
tools in the assessment of treatments. They are not,
however, without their flaws, if inappropriately designed
or reported [6,7]. In the 1990s, poor reporting and design
of clinical trials was identified as an important problem in
assessing their quality and validity. Initiatives were taken
to improve research design and reporting of clinical trials.
Recommendations were made to improve the internalis 5 (2006) 3 – 8uropean Cystic Fibrosis Society.
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randomisation, double-blinding and large sample sizes
[6,8]. The CONSORT guidelines [7], which made recom-
mendations about the reporting of clinical trials, were
formulated and have since been updated [9].
We have previously assessed all the RCTs on the CF
trials register from the inception of MEDLINE (1966) until
those published prior to 1998 [2]. We found that study
design was inadequate; 72% (359 /494) of RCTs had a
sample size of 30 or less, only 8.7% (44 /506) were
multicentre and 51.4% (260 /506) did not state whether
there was any blinding in the trial. We concluded that future
RCTs in CF would be more clinically useful if ‘‘higher
numbers of patients were recruited into large, well designed,
multicentre trials’’.
We were aware, from the CF register, that the number of
trials published in the last five years had increased
substantially. We wondered if this increase in numbers of
trials was associated with an improvement in quality. Thus,
the aim of our study was to compare the quality of design
and type of intervention studied in CF controlled trials
published in the five year period from 1998 to 2002 with
those published prior to 1998. We hypothesised that the later
epoch would be superior in design quality compared to the
earlier epoch.2. Materials and methods
The CF trials register was compiled from electronic
searches of CENTRAL (updated each new issue), quarterlyTable 1
The data collected on clinical controlled trials, with definitions of each data subs
Data Description
Year of publication If trials had multiple references, the year of th
conference abstracts, publication date was take
Type of report Full publication or conference abstract, if both
full paper was assessed for the database.
Type of controlled trial
i.e. RCT or CCT
RCT: ‘‘The authors state explicitly (usually by
that the groups compared in the trial were esta
CCT: All other eligible trials in terms of the U
Design
Blinding [1,5,7] Double: A study in which participants and tho
Single: A study in which either the participan
Open: The investigator recognises that blindin
assessing outcome are aware of treatment assi
Not stated: A study in which the author does
conducted a blinded study.
Parallel or crossover [2,20] Parallel: Two or more groups, studied simulta
Crossover: Subjects receive each treatment in
Placebo controlled [2,6] An inactive dummy with the same appearance
Multicentre or
single centre [2]
Multicentre: If the affiliations of the authors w
as multicentre [2].
Single: One centre of research in terms of aut
Sample size Number of CF patients studied. If a study recr
Intervention type Treatment was coded under different headings
e.g. antibiotic and physiotherapy.searches of MEDLINE, a search of EMBASE to 1995 and
the prospective handsearching of two journals — Pediatric
Pulmonology and the Journal of Cystic Fibrosis. Unpub-
lished work was identified by searching the abstract books
of three major CF conferences: the International Cystic
Fibrosis Conference, the European Cystic Fibrosis Confer-
ence and the North American Cystic Fibrosis Conference.
The full search strategy used to identify possible trials has
been described in detail elsewhere [10].
Controlled trials were eligible for inclusion if the patients
had CF, were carriers of the CF gene or were participating in a
CF antenatal or neonatal screening trial [2]. Any trials on
healthy participants were excluded. Trials had to be
randomised or possibly randomised, in accordance with the
US Cochrane Centre guidance [11]. This defines random-
isation as: ‘‘on the basis of the best available information
(usually from one or more published reports), it is judged that:
the individuals (or other units) followed in the trial were
definitely, or possibly, assigned prospectively to one of two
(or more) alternative forms of health care, using: random
allocation; or some quasi-random method of allocation (such
as alternation, date of birth or case record number)’’.
For all trials on the register specific pre-defined factors
were assessed from the original reports. These were the
intervention studied, the publication date and the design
type. The design factors assessed were whether the trial was
an RCT or a CCT, the degree of blinding and use of
placebos, whether a crossover or parallel design was used,
whether it was multicentre or single centre in design and the
sample size. Each of these aspects are defined in Table 1.
Any reports not available in English were translated andection
e earliest full publication was recorded. If trials were only available as
n as the year the abstract was available.
were available for one trial it was recorded as full and the first published
using some variant of the term Frandom_ to describe the allocation used)
blished by random allocation’’ [11].
S Cochrane Centre i.e. quasi-random or possibly random [11].
se assessing outcome are all unaware of treatment assignment.
t or those assessing outcome are unaware of treatment assignment.
g is not appropriate or possible and states that all participants and those
gnment.
not discuss blinding in his report and thus is presumed not to have
neously, with each assigned to a different treatment arm.
turn.
and taste as the agent under investigation.
ere from more than one CF centre, or if the RCT was referred to
hors’ affiliation to CF centre.
uited healthy volunteers, they were not included in sample size.
and thus trials could be assessed broadly by the intervention studied,
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Fig. 1. The number of randomised controlled trials and clinical controlled trials in cystic fibrosis published between 1961 and 2002.
Table 2
The design of controlled trials published in the periods 1961–1997 and
1998–2002
1961–1997 (%) 1998–2002 (%) All trials (%)
No. of trials 544 261 805
Parallel 245 (45) 130 (50) 375 (47)
Crossover 296 (54) 126 (48) 422 (52)
Unable to ascertain 3 (1) 5 (2) 8 (1)
Double-blind 199 (37) 85 (33) 284 (35)
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every trial. A subset of trials (January 1997–December
2002) was re-examined by a second assessor (TB), using the
same design factor definitions. The data collected from the
original papers were then compared to those drawn from the
register to ensure consistency. The raw data were then
assessed. We looked at the number of RCTs and CCTs
identified for each year of study.
We then compared the data over two epochs: 1961–1997
and 1998–2002 inclusive. The median sample size was
compared for the two epochs as a whole, for multicentre and
single centre trials and for each intervention type in the two
epochs. Median calculations were conducted, as a calcula-
tion of mean could lead to misinterpretation due to skewed
data. Trials where sample size was not stated were excluded
from that section of the analysis, as were screening trials,
since sample sizes were so large they would skew the data.
In addition, trials conducted as single-blind, or open,
were further assessed to determine whether the degree of
blinding could have been improved. In the case of open
trials, we considered whether those assessing outcomes
could be made unaware of treatment assignment and, thus,
whether the trial could have been single-blind. For both the
open and single-blind trials the intervention was then
considered, to see if the participant could have been blinded
to the intervention, thus indicating that the trial could have
been double-blind. In some cases this is possible, e.g. with
placebo use in antibiotic trials, but in others single-blinding
is appropriate as participants could not be blinded, e.g. in
physiotherapy trials studying postural drainage.Single-blind 28 (5) 3 (1) 31 (4)
Open 11 (2) 19 (7) 30 (4)
Not stated 306 (56) 154 (59) 460 (57)
Placebo controlled 165 (30) 82 (31) 247 (31)
Multicentre 59 (11) 65 (25) 124 (15)
Single centre 483 (89) 184 (70) 667 (83)
Unable to ascertain 2 (0.4) 12 (5) 14 (2)3. Results
The first cystic fibrosis RCT identified was published in
1961 [12]. This was a double-blind, placebo controlled,
parallel, single centre RCT, in which the effect of tocopherol
supplementation on muscle strength was evaluated in 45children with CF. Since then, until the end of 2002, a total of
805 trials were identified, 261 in the five years from 1998–
2002 (an increase of 48% from the previous 37 years). Of
the 805 trials, 631 (78%) were RCTs and 174 (22%) were
CCTs. From 1961–1997 there were 433 (80%) RCTs and
111 (20%) CCTs. In the epoch 1998–2002 there were 198
(76%) RCTs and 63 (24%) CCTs. Fig. 1 illustrates the
number of trials identified between 1961 and 2002, showing
RCTs and CCTs separately.
When the sample size of trials in each year was assessed
(RCTs and CCTs combined), the median sample size for
trials in the epoch 1961–1997 was 18 (IQ range 12–29),
whilst for 1998–2002 it was 21 (IQ range 13–41). The
median sample size of single centre trials in the earlier
epoch was 18, compared with 44 for multicentre trials. This
association between larger sample sizes in multicentre trials
was also seen in the later epoch, with a median of 19 for
single centre trials compared with 44 for multicentre trials.
The design of all trials was assessed according to epoch and
Table 3
The number of controlled trials and sample size for interventions in cystic fibrosis, from 1961–1997 and 1998–2002
Intervention 1961–1997 1998–2002
No. of trialsa (%) Median sample size Range No. of trialsb (%) Median sample size Range
Antibiotic 128 (24) 24 5–190 43 (17) 31 5–520
Physiotherapy 84 (16) 16 2–67 59 (21) 20 5–80
Mucolytic 60 (11) 20 4–968 30 (12.5) 24 7–474
Pancreatic enzyme 54 (10) 16.5 6–48 13 (5) 27 8–74
Nutrition 45 (8) 18 1–108 20 (8) 21 6–73
Gastro and liver 39 (7) 15 3–63 6 (2) 17 6–41
Anti-inflammatory 20 (4) 23.5 7–285 18 (7) 27 8–145
Bronchodilator 27 (6) 14 9–42 9 (4) 18 9–36
Gene therapy 8 (1) 12 6–16 10 (5) 13 6–44
Otherc 64 (12) 16.5 5–397 46 (18) 19 3–749
Screening 8 (1) 1846.5 309–65,0341 1 (0.5) 109 109
Total 537 255
a Excludes 7 trials where sample size was not stated.
b Excludes 6 trials where sample size was not stated.
c The intervention group Fother_ includes aerosol delivery, oxygen therapy, vaccines, endocrine studies, complementary therapies and psychological studies.
Note that aerosol delivery trials compare delivery devices, not pharmacological effectiveness of a drug being delivered. Thus whilst the drugs delivered may
have been antibiotics or bronchodilators, if the focus of the study was aerosol delivery, not pharmacology, trials were coded as aerosol delivery trials i.e. other.
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blinding in over half the trials as no reference to blinding
was made in the report.
In an assessment of whether blinding could have been
improved, it was found that of the 31 single-blind trials, 27
could have been double-blind if trial design had been
optimal. The remaining four trials were appropriately
designed as single-blind. Of the 30 open trials, 19 could
have been double-blind and the remaining 11 could have
been single-blind. The trials, which could have been
designed as double-blind with the use of placebos, were
trials of interventions such as antibiotics, mucolytics and
vaccines. Those that could have been single-blind, or where
single-blinding was appropriate, were evaluating interven-
tions, which would be impractical to double-blind, such as
nebuliser device preference, capsule size and physiotherapy
techniques.
The trials were also assessed with relation to the type of
intervention they studied and sample size. These data were
categorized into the two epochs, as shown in Table 3.4. Discussion
Since 1961 the number of controlled trials in people with
CF has increased progressively. About a third of all trials
published over the 42 years since then were published in the
last five. Despite this, when comparing the recent five years
with the previous 37 years, the only notable change in trial
design or characteristics was an increase in the number of
multicentre trials in the later epoch.
The strength of this study lies in the fact that a large
number of trials were assessed, over a prolonged period,
using pre-defined design factor definitions to determine the
quality of controlled trials in CF. We only assessed a few
specific design factors and whilst the factors we assessed areconsidered integral to design [13,14] and give a picture of
design quality, one must remember the other important
features of design quality, such as intention-to-treat analysis
and randomisation in detail i.e. sequence generation and
allocation concealment [9]. It is also important to note that
whilst our primary assessment was of trial design quality, as
this was assessed from published work, we also inadver-
tently assessed reporting quality, as the two are interlinked.
Due to the large number of trials assessed, we did not
contact authors for clarification and had to rely upon their
reporting, which as we have highlighted is not always
optimal.
We did not perform a direct comparison of our
previously formulated results [2] (1966–1997) with the
recent dataset (1998–2002). There are several reasons for
this. Firstly, Cheng et al. [2] only studied RCTs and we
studied all controlled trials. Secondly, Cheng et al. [2]
classified some studies as RCTs which, in the light of more
specific definitions, are now classified as CCTs. Finally,
continued searching has identified more trials prior to 1997
and some previously available only as a conference abstract
are now published in full, allowing a more comprehensive
analysis.
We observed that the percentage of RCTs and CCTs in
each epoch was similar (80% RCT in 1961–1997; 76%
RCT in 1998–2002). This high percentage of RCTs is
encouraging as RCTs are of superior validity compared to
CCTs, due to more stringent allocation of subjects.
Sample size has not substantially improved from a
median of 18 (IQ 12–29) in the earlier period, to 21 (IQ
13–41) in 1998–2002. The power of these studies is poor
and this finding concurs with previous studies of RCTs in
general health [15] and children [16]. One would have
hoped that the sample size would have been larger as the
trials on the Cochrane database are at least phase II trials and
mainly phase III trials. To explain this statement it is helpful
T.A. Briggs et al. / Journal of Cystic Fibrosis 5 (2006) 3–8 7to consider types and stages of research conducted when one
is trying to evaluate a treatment. As Haynes [17] stated there
are three concepts related to testing health care interven-
tions: Efficacy—can it work? i.e. does the treatment do
more good than harm in ideal circumstances. Effective-
ness—does it work in practice? i.e. does the treatment still
do more good than harm when utilised in real life circum-
stances. Efficiency—is it worth it? i.e. is the intervention
cost effective. To assess efficacy and effectiveness research
of a treatment may pass through three phases of trial
designs.
Phase I trials are the first studies conducted in humans to
evaluate a new drug, the primary focus is safety. They are
mostly conducted on healthy volunteers to assess drug
metabolism and potential adverse side effects. These trials
are often not randomised or controlled [18].
After a drug is shown to be safe in a phase I trial a phase
II trial can commence. Here a small number of patients
(n =20) are given the drug in order to establish the efficacy
of different doses and frequency of administration. Phase II
trials often take an explanatory role in that there are strict
inclusion criteria and stringent control of variables and test
conditions. They are often not randomised and treatments
are compared with placebo or no treatment [18,19].
Once a drug is found to be reasonably effective in phase
II trials, a phase III trial can be designed and conducted.
These are typically effectiveness trials of a pragmatic nature,
as they seek to compare the new drug with an existing drug
(which is often the standard treatment). They include all
relevant participants and test large numbers in real life
conditions, with clinically relevant outcomes. Most phase III
trials are RCTs [18,19].
From this explanation one can appreciate that our study
did not assess phase I trials, as these are generally conducted
on healthy volunteers and we excluded all individuals who
did not have CF. Also they are not randomised and we only
assessed clinical controlled trials. A proportion of the trials
we assessed were phase II and as stated these do have a
smaller sample size. Again any phase II trials which were
not clinical controlled trials were not included. A large
proportion of our trials were phase III in nature. Thus we do
not feel that the exceptionally small median sample sizes
identified, can be explained by the fact that a proportion of
the trials were phase II.
Whilst it is appreciated that trial eligibility criteria and
ethical considerations in children may create difficulties
with recruitment in an already relatively small patient pool,
the problem of small sample size can be overcome by
recruiting participants from several sites. Multicentre trials
not only improve statistical power, they also enhance
external validity and, through rapid recruitment, give more
timely results [20]. It was therefore encouraging to observe
an increase in multicentre trials, from 11% in 1961–1997, to
25% in 1998–2002. Campbell et al. [16] report that 18% of
RCTs published in Archives of Disease in Childhood
between 1982–1996, were multicentre trials. In this study,the median sample size in multicentre trials was 80,
compared with only 36 in single centre trials. We found
that the median sample sizes in multicentre, compared with
single centre, trials were much greater and this finding was
stable over both epochs. This suggests that, where the
number of potentially eligible participants is limited, the
only practical way to increase sample size in trials is for the
trial to be multicentre, rather than single centre. We do,
however, acknowledge the practical difficulties of multi-
centre trials in terms of logistics, costs and inter-centre
communication and appreciate that in phase II trials it may
be more practical to perform single centre trials. We are also
aware that with only a limited patient population a few large
trials, such as those by Ramsey et al. [21] and Saiman et al.
[22], will ‘‘tie-up’’ patients from participating in other trials.
However the advantages gained from large multicentre trials
are such that we must strive to overcome these obstacles, by
initiating large phase III trials in stages, if necessary, and
improving funding and education.
It was striking that all other characteristics of trials were
very similar between the two epochs. We commented
previously [2] on the high proportion of trials which were
of crossover design. Whilst this enables inter-patient
comparisons, crossover design is inappropriate to assess
many interventions in chronic diseases, such as CF, where
treatment effects may carry over from one intervention to
the next and where treatments may affect the natural history
of the disease [2,23,24]. Campbell et al. [16] found that, of
the respiratory medicine articles published in Archives of
Disease in Childhood, 60 out of 69 (87%) were parallel in
design, but many of these may have been trials in acute
conditions such as childhood pneumonia.
There was no evidence of improvement in reducing
ascertainment bias by improved blinding of investigators
and participants. However, the main problem was that in
over half of the studies blinding could not be assessed, due
to poor reporting. Blinding seeks to prevent ascertainment
bias and trials which are not double-blind yield larger
estimates of treatment effects than double-blind trials, with
exaggeration of the odds ratio reported to be 17% [14,25].
These poor results illustrate inadequate design and report-
ing, which has persisted over time. This finding concurs
with previous studies [2,16,26]. Of the 61 trials, which
stated that they were single-blind or open in design, it
appeared that 46 could have been double-blinded. We
recognise that this assessment is superficial and, as
mentioned, authors were not contacted to discuss reasons
for design choices. However, we feel that researchers can
generally be masked to the intervention and those authors
who do not do this should justify it in reporting.
The most frequent interventions studied were the same
in both epochs; antibiotics and physiotherapy. The median
sample size varied with each type of intervention. Antibiotic
trials had the largest median sample size at 24 (1961–1997)
and 31 (1998–2002). Gene therapy studies had the smallest
median sample size at 12 (1961–1997) and 13 (1998–
T.A. Briggs et al. / Journal of Cystic Fibrosis 5 (2006) 3–882002), which was predictable, as these are largely phase II,
exploratory trials.
As has been highlighted above, many of our findings are
similar to those in other disease fields [16,26,27]. One study
with slightly different findings was in acute stroke. Bath et
al. [28] concluded that although, in trials of stroke, overall
methodology was poor, it improved over time. However,
Bath et al. [28] assessed 88 design factors and then
calculated an overall assessment of design quality, so some
design factors may have been compensated for by other
more general features. They did, however, demonstrate a
median sample size of 80 and a multicentre trial rate of
45.1% in their survey of acute stroke trials. One explanation
for the superior design of these trials is that the prevalence
of stroke is much higher than CF and also that the studies
selected were an elite group of parallel design RCTs,
published in peer review journals.
Although this study highlights some important points
about CF clinical trials, it also raises several questions and
ideas for future study. For example, if the increase in
multicentre trials is sustained, will this lead to a demon-
strable improvement in sample size and proportion of
parallel trials? What are the barriers preventing researchers
conducting double-blind trials? It would be interesting to
assess other aspects of design, such as intention-to-treat
analysis, generation of randomisation, concealment of
treatment and allocation sequence [6,8,13], to see if they
are also inadequately conducted.
We therefore hope that the insights provided by our work
will act to encourage CF investigators and journal editors to
strive for improved design quality of clinical trials. This will
enable the reader to assess the validity of the trial, which is
an essential prerequisite for evidence-based practice and a
necessary element of systematic reviews.References
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